17509097

Source:http://linkedlifedata.com/resource/pubmed/id/17509097

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0002594, umls-concept:C0021149, umls-concept:C0021747, umls-concept:C0030705, umls-concept:C0035525, umls-concept:C0229671, umls-concept:C0524910, umls-concept:C0702240, umls-concept:C1522326, umls-concept:C1880022
pubmed:issue	11
pubmed:dateCreated	2007-5-18
pubmed:abstractText	A virological response to pegylated-interferon and ribavirin is typically associated with a prompt fall in serum transaminases. For some patients, transaminases rise during treatment.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8707234
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antiviral Agents, http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha, http://linkedlifedata.com/resource/pubmed/chemical/Polyethylene Glycols, http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Ribavirin, http://linkedlifedata.com/resource/pubmed/chemical/Transaminases, http://linkedlifedata.com/resource/pubmed/chemical/interferon alfa-2a, http://linkedlifedata.com/resource/pubmed/chemical/interferon alfa-2b, http://linkedlifedata.com/resource/pubmed/chemical/peginterferon alfa-2a, http://linkedlifedata.com/resource/pubmed/chemical/peginterferon alfa-2b
pubmed:status	MEDLINE
pubmed:month	Jun
pubmed:issn	0269-2813
pubmed:author	pubmed-author:HubscherSS, pubmed-author:LamW WWW, pubmed-author:MutimerDD, pubmed-author:O'DonnellKK, pubmed-author:ThorburnDD, pubmed-author:ThurairajahP HPH, pubmed-author:WhiteAA
pubmed:issnType	Print
pubmed:day	1
pubmed:volume	25
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	1293-300
pubmed:dateRevised	2011-11-17
pubmed:meshHeading	pubmed-meshheading:17509097-Administration, Cutaneous, pubmed-meshheading:17509097-Administration, Oral, pubmed-meshheading:17509097-Adult, pubmed-meshheading:17509097-Antiviral Agents, pubmed-meshheading:17509097-Drug Therapy, Combination, pubmed-meshheading:17509097-Female, pubmed-meshheading:17509097-Hepatitis C, Chronic, pubmed-meshheading:17509097-Humans, pubmed-meshheading:17509097-Interferon-alpha, pubmed-meshheading:17509097-Male, pubmed-meshheading:17509097-Middle Aged, pubmed-meshheading:17509097-Polyethylene Glycols, pubmed-meshheading:17509097-Prevalence, pubmed-meshheading:17509097-Recombinant Proteins, pubmed-meshheading:17509097-Retrospective Studies, pubmed-meshheading:17509097-Ribavirin, pubmed-meshheading:17509097-Transaminases, pubmed-meshheading:17509097-Treatment Outcome
pubmed:year	2007
pubmed:articleTitle	Incidence and characterization of serum transaminases elevations in pegylated interferon and ribavirin treated patients with chronic hepatitis C.
pubmed:affiliation	The Liver Unit, Queen Elizabeth Hospital, University Hospital of Birmingham NHS Trust, Edgbaston, Birmingham, UK.
pubmed:publicationType	Journal Article